Eisai Co., Ltd. announced today that the company will have a total of nine poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa) at the 77th American Epilepsy Society Annual Meeting (AES 2023), to be held in Orland, Florida and virtually from December 1-5, 2023.
More info..

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) was awarded both the Best New Drug and Clinical Advance of the Year for the Phase III Clarity AD study at the Scrip Awards 2023, held by Citeline.
More info..

Eisai Co. Ltd. announced today that TIME has selected Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) as one of THE BEST INVENTIONS of 2023 in the Medical Care category.
More info..

Eisai Co. Ltd announced today that the company will present new data from the phase 3 Clarity AD study for its Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use and new data on the subcutaneous formulation in development at the 16th annual Clinical Trials on Alzheimer's Disease (CTAD) conference.
More info..

Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2023, which is taking place virtually and in-person in Madrid, Spain from October 20 to 24.
More info..

Eisai Co., Ltd. hereby announcesthat the Company has today decided to absorb and merge with KAN Research Institute, Inc., the Company's wholly owned subsidiary on April 1, 2024.
More info..

Eisai Co., Ltd. announced today that it has launched a new "Innovation" page on its corporate website.
More info..

Tokio Marine & Nichido Fire Insurance Co., Ltd. and Eisai Co., Ltd. announced that they have co-developed "Dementia Care Support Insurance" to financially support early detection and early treatment for dementia as a part of their business alliance for the realization of a Dementia Inclusive Society.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" Intravenous Infusion (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD).
More info..

Eisai Co., Ltd. announced today on World Alzheimer's Day, that it has released a dementia awareness video, "Life Goes On 2023: Two Memories, One Story", on its dementia information website "Sodan.e-65" and YouTube, which are intended to deepen the understanding of dementia.
More info..

Eisai Co., Ltd. announced today that it has established a digital business company Theoria technologies Co., Ltd. ("Theoria technologies") which will accelerate the development of a dementia ecosystem. Theoria technologies is a wholly owned subsidiary of Eisai.
More info..

Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 22nd consecutive year since its initial inclusion in 2002.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the results of a detailed analysis of the Phase 3 Clarity AD study demonstrated that lecanemab-irmb (generic name, U.S. brand name: LEQEMBI) treatment showed reductions in amyloid-beta (Abeta) pathology and downstream biomarker changes.
More info..

Eisai Co. Ltd announced today that the company will present the latest findings on its Alzheimer's disease (AD) pipeline and research, including Eisai's anti-amyloid beta (Abeta) protofibril* antibody for the treatment of Alzheimer's disease (AD).
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI
More info..

Eisai, Gates Ventures, Health Data Research UK (HDR UK), LifeArc and The University of Edinburgh announced today a new two-year collaborative research agreement.
More info..

Eisai Co., Ltd. announced today that brain health checks utilizing "NouKNOW" (pronounced "NOH-NOH"), Eisai's digital tool for self-assessment of cognitive function, will continue to be promoted as part of the FY2023 dementia examination project, conducted by Bunkyo City, Tokyo.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from Eisai's Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use for the treatment of Alzheimer's disease (AD).
More info..

This application is the first application for lecanemab in Asia outside of Japan and China. Eisai plans to submit additional applications in other Asian countries.
More info..

Eisai Co., Ltd. announced a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO), will be given at the 37th annual meeting of the Associated Professional Sleep Societies (SLEEP 2023), to be held from June 3 to 7, 2023 in Indianapolis, IN, the United States.
More info..

These data will be presented on Monday, June 5 at 11:54 a.m. Central Daylight Time during an oral abstract session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #4502).
More info..

Eisai Co., Ltd. has announced that it will grant a total of 625 million yen to the Global Health Innovative Technology Fund ("GHIT Fund") to fund the third phase of its activities, which will take place in the five-year period from FY2023 to FY2027.
More info..

Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO23), which is taking place virtually and in-person in Chicago, Illinois from June 2 to 6.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a Marketing Authorization Application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain, to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril* antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain.
More info..

Eisai Co., Ltd. announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd., for BB-1701, an antibody-drug conjugate (ADC) with option rights for a strategic collaboration.
More info..

Eisai Co., Ltd. today announced the completion of a major renovation of its Tsukuba Research Laboratories (Ibaraki, Japan), which is a part of strategic investment to execute Eisai's medium-term business plan "EWAY Future & Beyond".
More info..

Eisai Co., Ltd. today announced an article about long-term health outcomes of anti-amyloid-beta (Aβ) protofibril* antibody lecanemab in people living with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) using simulation modeling was published in the peer-reviewed journal Neurology and Therapy.
More info..

Eisai Co., Ltd. announced today that it has entered into an agreement with the National Cancer Center to collaborate on investigator-initiated clinical research for the EZH2 inhibitor tazemetostat hydrobromide (generic name, product name "Tazverik Tablets 200 mg", "tazemetostat") based on "Patient-Proposed Healthcare Services" system.
More info..